Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks. Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion in revenue from emerging businesses by the mid-2030s. Merck & Co., Inc. (NYSE:MRK) ex ...